Foundation Medicine Inc (FMI) CFO Sells $222,920.00 in Stock

Foundation Medicine Inc (NASDAQ:FMI) CFO Jason Ryan sold 5,573 shares of the stock in a transaction that occurred on Friday, June 2nd. The stock was sold at an average price of $40.00, for a total transaction of $222,920.00. Following the sale, the chief financial officer now owns 78,405 shares in the company, valued at $3,136,200. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Jason Ryan also recently made the following trade(s):

  • On Tuesday, April 18th, Jason Ryan sold 503 shares of Foundation Medicine stock. The stock was sold at an average price of $34.55, for a total transaction of $17,378.65.
  • On Thursday, March 16th, Jason Ryan sold 12,500 shares of Foundation Medicine stock. The stock was sold at an average price of $31.68, for a total transaction of $396,000.00.

Shares of Foundation Medicine Inc (NASDAQ:FMI) traded up 0.71% during midday trading on Friday, hitting $42.85. 100,197 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $36.50 and its 200-day moving average is $27.54. Foundation Medicine Inc has a 1-year low of $16.95 and a 1-year high of $43.15. The stock’s market cap is $1.53 billion.

Foundation Medicine (NASDAQ:FMI) last issued its earnings results on Tuesday, May 9th. The company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.02) by $0.29. The firm had revenue of $26.32 million during the quarter, compared to the consensus estimate of $29.07 million. Foundation Medicine had a negative return on equity of 127.98% and a negative net margin of 176.44%. The firm’s revenue for the quarter was down 13.3% compared to the same quarter last year. During the same period last year, the business earned ($0.50) earnings per share. Analysts predict that Foundation Medicine Inc will post ($4.40) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Foundation Medicine (NASDAQ:FMI)

COPYRIGHT VIOLATION WARNING: This story was first posted by Mideast Time and is the property of of Mideast Time. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at https://www.mideasttime.com/foundation-medicine-inc-fmi-cfo-sells-222920-00-in-stock/1766554.html.

A number of equities research analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Foundation Medicine from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. ValuEngine upgraded shares of Foundation Medicine from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. BTIG Research upgraded shares of Foundation Medicine from a “neutral” rating to a “buy” rating and set a $39.00 target price on the stock in a report on Monday, May 15th. William Blair reiterated a “buy” rating on shares of Foundation Medicine in a report on Monday, April 3rd. Finally, Janney Montgomery Scott upgraded shares of Foundation Medicine from a “sell” rating to a “neutral” rating and set a $31.00 target price on the stock in a report on Tuesday, March 7th. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $30.25.

A number of hedge funds and other institutional investors have recently modified their holdings of the company. GSA Capital Partners LLP boosted its position in shares of Foundation Medicine by 24.1% in the fourth quarter. GSA Capital Partners LLP now owns 11,500 shares of the company’s stock valued at $204,000 after buying an additional 2,234 shares during the period. Nuveen Fund Advisors LLC purchased a new position in shares of Foundation Medicine during the third quarter valued at approximately $221,000. Creative Planning boosted its position in shares of Foundation Medicine by 10.0% in the first quarter. Creative Planning now owns 4,400 shares of the company’s stock valued at $142,000 after buying an additional 400 shares during the period. Gilder Gagnon Howe & Co. LLC boosted its position in shares of Foundation Medicine by 0.5% in the first quarter. Gilder Gagnon Howe & Co. LLC now owns 1,610,865 shares of the company’s stock valued at $51,950,000 after buying an additional 7,347 shares during the period. Finally, Peconic Partners LLC purchased a new position in shares of Foundation Medicine during the third quarter valued at approximately $2,105,000. 31.44% of the stock is owned by hedge funds and other institutional investors.

About Foundation Medicine

Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:FMI”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Foundation Medicine Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.